Background
Methods
Structural gene analysis
In silico target gene prediction
Functional annotation clustering and pathway enrichment analysis
Predicted functional effect of rs37464443 SNP
Study participants
Spirometry and methacholine challenge test
Biochemical analysis
Genotyping of seed region variant
Statistical analysis
Results
Structural gene analysis and comparative genomics
In silico target gene prediction
Functional annotation clustering and pathway enrichment analysis
Predicted functional effect of rs3746444 SNP
Genotyping of rs3746444 polymorphism in the study groups
Asthma | Controls |
P value | Crude OR (95%CI) | Adjusted OR (95%CI) a
| ||
---|---|---|---|---|---|---|
DISCOVERY STAGE | ||||||
Total number | (n = 96) | (n = 96) | ||||
Genotype frequency | ||||||
Co-Dominant model
| AA | 20 (20.8) | 56 (58.3) |
<0.001
| 1.0 | 1.0 |
AG | 38 (39.6) | 30 (31.3) |
3.54 (1.76–7.14)
|
3.67 (1.74–7.77)
| ||
GG | 38 (39.6) | 10 (10.4) |
10.6 (4.48–25.2)
|
10.9 (4.41–27.3)
| ||
Dominant model
| AA | 20 (20.8) | 56 (58.3) | 1.0 | ||
AG + GG | 76 (79.2) | 40 (41.7) |
5.32 (2.81–10.1)
| |||
P-HWE | 0.064 | 0.078 | ||||
Allele frequency | ||||||
Allelic model
| A | 78 (40.6) | 142 (73.9) |
<0.001
| 1.0 | |
G | 114 (59.3) | 50 (26.04) |
4.1 (2.69–6.39)
| |||
Carriage rate | ||||||
A | 58 (60.4) | 86 (89.6) |
<0.001
|
0.17 (0.08–0.38)
|
0.29 (0.12–0.70)
| |
G | 76 (79.2) | 40 (41.7) |
<0.001
|
4.71 (2.52–8.80)
|
3.22 (1.57–6.62)
| |
REPLICATION STAGE | ||||||
Total number | (n = 115) | (n = 204) | ||||
Genotype frequency | ||||||
Co-Dominant model
| AA | 14 (12.2) | 82 (40.2) |
<0.001
| 1.0 | 1.0 |
AG | 48 (41.7) | 95 (46.6) |
2.95 (1.52–5.75)
|
2.79 (1.46–5.06)
| ||
GG | 53 (46.1) | 27 (13.2) |
11.4 (5.52–23.9)
|
10.8 (4.65–20.3)
| ||
Dominant model
| AA | 14 (12.2) | 82 (40.2) |
<0.001
| 1.0 | |
AG + GG | 101 (87.8) | 122 (59.8) |
4.84 (2.59–9.06)
| |||
P-HWE | 0.542 | 0.950 | ||||
Allele frequency | ||||||
Allelic model
| A | 76 (33.1) | 259 (63.5) |
<0.001
| 1.0 | |
G | 154 (66.9) | 149 (36.5) |
3.52 (2.50–4.95)
| |||
Carriage rate | ||||||
A | 62 (53.9) | 177 (86.8) |
<0.001
|
0.17 (0.1–0.30)
|
0.23 (0.2–0.34)
| |
G | 101 (87.8) | 122 (59.8) |
<0.001
|
4.84 (2.59–9.06)
|
4.79 (2.64–8.9)
| |
OVERALL ANALYSIS | ||||||
Total number | (n = 211) | (n = 300) | ||||
Genotype frequency | ||||||
Co-Dominant model
| AA | 34 (16.1) | 138 (46.0) |
<0.001
| 1.0 | 1.0 |
AG | 86 (40.8) | 155 (41.7) |
2.25 (1.42–3.56)
|
2.13 (1.24–3.46)
| ||
GG | 91 (43.1) | 37 (12.3) |
9.98 (5.84–17.05)
|
9.52 (5.61–16.5)
| ||
Dominant model
| AA | 34 (16.1) | 138 (46.0) | |||
AG + GG | 177 (83.9) | 162 (54.0) |
<0.001
| 1.0 | ||
P-HWE | 0.079 | 0.507 |
4.43 (2.88–6.82)
| |||
Allele frequency | ||||||
Allelic model
| A | 154 (36.5) | 431 (62.3) |
<0.001
| 1.0 | |
G | 268 (63.5) | 229 (34.7) |
3.27 (2.53–4.22)
| |||
Carriage rate | ||||||
A | 120 (56.9) | 263 (87.7) |
<0.001
|
0.18 (0.12–0.28)
|
0.12 (0.08–0.21)
| |
G | 175 (82.9) | 162 (54.0) |
<0.001
|
4.14 (2.71–6.33)
|
3.96 (2.14–5.9e)
|
Characteristics | No | rs3746444 genotypes |
P value | ||
---|---|---|---|---|---|
AA | AG | GG | |||
Total number (%) | 211 | 34 (16.1) | 86 (40.8) | 91 (43.1) | |
Mean age, years | |||||
Children (6–11) | 144 | 24 (16.7) | 61 (42.4) | 59 (41.0) | 0.650 |
Adolescents (12–18) | 67 | 10 (14.9) | 25 (37.3) | 32 (47.8) | |
Gender | |||||
Female | 118 | 18 (15.3) | 53 (44.9) | 47 (39.8) | 0.380 |
Male | 93 | 16 (17.2) | 33 (35.5) | 44 (47.3) | |
FH of asthma | 56 | 8 (14.3) | 21 (37.5) | 27 (48.2) | 0.666 |
Pubertal status | 109 | 19 (17.4) | 46 (42.2) | 44 (40.4) | 0.685 |
Obesity | 23 | 3 (13.0) | 11 (47.8) | 9 (39.2) | 0.838 |
Residence | |||||
Urban | 75 | 12 (16.0) | 29 (38.7) | 34 (45.3) | 0.879 |
Rural | 136 | 22 (16.2) | 57 (41.9) | 57 (41.9) | |
Mean age at onset, years | 3.82 ± 1.6 | 3.58 ± 1.9 | 3.25 ± 1.8 | 0.245 | |
Early (≤3y) | 99 | 10 (10.1) | 39 (39.4) | 50 (50.5) |
0.036
|
Late (>3y) | 112 | 24 (21.4) | 47 (42.0) | 41 (36.6) | |
Asthma duration, years | 5.55 ± 2.5 | 5.96 ± 2.3 | 6.23 ± 2.5 | 0.245 | |
Asthma phenotypes | |||||
Atopic asthma | 166 | 28 (16.8) | 66 (39.8) | 72 (43.4) | 0.611 |
Non-atopic asthma | 15 | 4 (26.7) | 5 (33.3) | 6 (40.0) | |
Aspirin-sensitive asthma | 25 | 1 (4.0) | 13 (52.0) | 11 (44.0) | |
Exercise-induced asthma | 5 | 1 (20.0) | 2 (40.0) | 2 (40.0) | |
Symptoms | |||||
Daytime symptoms >2/week | 103 | 14 (13.6) | 42 (40.8) | 47 (45.6) | 0.581 |
Nocturnal symptoms | 39 | 6 (15.4) | 18 (46.2) | 15 (38.6) | 0.741 |
Reliever use >2/week | 74 | 14 (189) | 35 (47.3) | 25 (33.8) | 0.131 |
Activity limitations | 69 | 11 (15.9) | 28 (40.6) | 30 (43.5) | 0.997 |
Asthma control | |||||
Well controlled | 76 | 16 (21.1) | 28 (36.8) | 32 (42.1) | 0.122 |
Partly controlled | 99 | 9 (9.1) | 44 (44.4) | 46 (46.5) | |
Uncontrolled | 36 | 9 (25.0) | 14 (38.9) | 13 (36.1) | |
Asthma severity | |||||
Mild | 88 | 15 (17.0) | 35 (39.8) | 38 (43.2) | 0.506 |
Moderate | 90 | 15 (16.7) | 33 (36.7) | 42 (467) | |
Severe | 33 | 4 (12.1) | 18 (54.5) | 11 (33.3) | |
Co-morbidities | 105 | 17 (16.2) | 43 (41.0) | 45 (42.8) | 0.997 |
Airway hyper-responsiveness | |||||
Normal | 61 | 11 (18.0) | 20 (32.8) | 30 (49.2) | 0.127 |
Borderline | 61 | 13 (21.3) | 31 (50.8) | 17 (27.9) | |
Mild/moderate | 54 | 7 (13.0) | 21 (38.9) | 26 (48.1) | |
Severe | 35 | 3 (8.6) | 14 (40.0) | 18 (51.4) | |
Lab tests | |||||
Total IgE (IU/ml) | 211 | 60 (42–121) | 162 (15–122) | 45 (15–120) | 0.307 |
AEC (×106/L) | 211 | 111 (31.5–340) | 88 (23.7–245) | 65 (25–230) | 0.571 |